- Trials with a EudraCT protocol (29)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
29 result(s) found for: pancreatic adenocarcinoma.
Displaying page 1 of 2.
EudraCT Number: 2007-000557-61 | Sponsor Protocol Number: 2/2007/O/Sper | Start Date*: 2007-02-15 | |||||||||||
Sponsor Name:AZIENDA OSPEDALIERA DI BOLOGNA POLICLINICO S. ORSOLA M. MALPIGHI | |||||||||||||
Full Title: PROSPECTIVE RANDOMIZED STUDY ON NEOADJUVANT CHEMORADIOTHERAPY PLUS SURGERY VS. SURGERY ALONE IN PATIENTS WITH RESECTABLE PANCREATIC ADENOCARCINOMA' | |||||||||||||
Medical condition: PANCREATIC ADENOCARCINOMA' | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2010-024287-17 | Sponsor Protocol Number: PACT-18 | Start Date*: 2011-02-03 | |||||||||||
Sponsor Name:FONDAZIONE CENTRO S. RAFFAELE DEL MONTE TABOR | |||||||||||||
Full Title: Salvage therapy with trabectidin in metastatic pancreatic adenocarcinoma: a single-arm phase II trial. | |||||||||||||
Medical condition: metastatic pancreatic adenocarcinoma | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2009-013029-41 | Sponsor Protocol Number: PACT-13 | Start Date*: 2009-07-07 | |||||||||||
Sponsor Name:FONDAZIONE CENTRO S. RAFFAELE DEL MONTE TABOR | |||||||||||||
Full Title: Proteomic profile analysis to classify advanced pancreatic adenocarcinoma patients for clinical outcome after treatment with PDXG (cisplatin, docetaxel, capecitabine, gemcitabine) or PEXG (cisplati... | |||||||||||||
Medical condition: patients affected by adenocarcinoma at stage III or IV who are candidate to receive upfront chemotherapy according to PDXG or PEXG regimen. | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2013-003080-59 | Sponsor Protocol Number: GIP-2 | Start Date*: 2013-12-19 | |||||||||||
Sponsor Name:Azienda Ospedaliero-Universitaria Pisana | |||||||||||||
Full Title: PHASE III ITALIAN MULTICENTER STUDY COMPARING THE COMBINATION OF 5-FLUOROURACIL/FOLINIC ACID, OXALIPLATIN AND IRINOTECAN (FOLFOXIRI) VERSUS GEMCITABINE AS ADJUVANT TREATMENT FOR RESECTED PANCREATIC... | |||||||||||||
Medical condition: Stage I-III resected pancreatic cancer | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2010-020979-23 | Sponsor Protocol Number: PACT-17 | Start Date*: 2010-07-21 | |||||||||||
Sponsor Name:FONDAZIONE CENTRO S. RAFFAELE DEL MONTE TABOR | |||||||||||||
Full Title: Randomized fase II study using chemiotherapy with metformine in patients affected by pancreas metastatic cancer. | |||||||||||||
Medical condition: pancreas metastatic tumor | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2010-019942-23 | Sponsor Protocol Number: PACT-15 | Start Date*: 2010-07-02 | |||||||||||
Sponsor Name:FONDAZIONE CENTRO S. RAFFAELE DEL MONTE TABOR | |||||||||||||
Full Title: Randomized, fase II-III study of peri and post surgery chemiotherapy in removable pancreas carcinoma | |||||||||||||
Medical condition: removable pancreas cancer | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2005-005063-29 | Sponsor Protocol Number: GEMOXA001 | Start Date*: 2006-01-01 | |||||||||||
Sponsor Name:ISTITUTI FISIOTERAPICI OSPITALIERI | |||||||||||||
Full Title: Induction Chemotherapy with Gemcitabine-Oxaliplatin GEM-OXA followed by concomitant weekly Gemcitabine plus Radiotherapy GEM/RT in Locally Advanced, Unresectable Pancreatic Cancer A Phase II ... | |||||||||||||
Medical condition: Locally advanced pancreatic cancer | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2014-000805-11 | Sponsor Protocol Number: C26003 | Start Date*: 2014-09-09 | |||||||||||||||||||||
Sponsor Name:Millennium Pharmaceuticals, Inc. | |||||||||||||||||||||||
Full Title: Phase 2 Trial of MLN0264 in Previously Treated Patients With Advanced or Metastatic Pancreatic Adenocarcinoma Expressing Guanylyl Cyclase C (GCC) | |||||||||||||||||||||||
Medical condition: Metastatic or Advanced Adenocarcinoma of the Pancreas Expressing Guanylyl Cyclase C (GCC) | |||||||||||||||||||||||
|
|||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||||||||||||
Trial protocol: IT (Ongoing) ES (Prematurely Ended) BE (Prematurely Ended) GB (Prematurely Ended) | |||||||||||||||||||||||
Trial results: View results |
EudraCT Number: 2014-001408-23 | Sponsor Protocol Number: ABI-007-PANC-007 | Start Date*: 2015-03-05 | |||||||||||
Sponsor Name:Celgene Corporation | |||||||||||||
Full Title: NAB-PACLITAXEL (ABRAXANE®) PLUS GEMCITABINE IN SUBJECTS WITH LOCALLY ADVANCED PANCREATIC CANCER (LAPC): AN INTERNATIONAL, OPEN-LABEL, MULTI-CENTER, PHASE 2 STUDY (LAPACT) | |||||||||||||
Medical condition: Locally advanced pancreatic cancer | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Ongoing) ES (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2011-004687-30 | Sponsor Protocol Number: MM-398-07-03-01 | Start Date*: 2012-03-06 | |||||||||||||||||||||
Sponsor Name:Merrimack Pharmaceuticals Inc. | |||||||||||||||||||||||
Full Title: NAPOLI 1: A Randomized, Open Label Phase 3 Study of MM-398, with or without 5-Fluorouracil and Leucovorin, versus 5-Fluorouracil and Leucovorin, in Patients with Metastatic Pancreatic Cancer Who h... | |||||||||||||||||||||||
Medical condition: Metastatic Pancreatic Cancer | |||||||||||||||||||||||
|
|||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||||||||||||
Trial protocol: HU (Completed) CZ (Completed) GB (Ongoing) IT (Completed) | |||||||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2013-003866-15 | Sponsor Protocol Number: ABI-007-PANC-CA046C | Start Date*: 2014-01-24 | |||||||||||
Sponsor Name:Celgene Corporation | |||||||||||||
Full Title: MPACT EXTENSION STUDY: MULTICENTER, SURVIVAL DATA COLLECTION IN SUBJECTS PREVIOUSLY ENROLLED IN PROTOCOL CA046 | |||||||||||||
Medical condition: Metastatic Adenocarcinoma of the Pancreas | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: AT (Completed) ES (Ongoing) IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2006-005314-12 | Sponsor Protocol Number: WX/60-004 | Start Date*: 2007-01-05 | |||||||||||
Sponsor Name:Wilex AG | |||||||||||||
Full Title: A randomised, open label, Phase II Proof of Concept study of WX-671 in combination with gemcitabine vs gemcitabine in patients with locally advanced, non-resectable pancreatic cancer in order to ev... | |||||||||||||
Medical condition: Locally advanced, non-resectable pancreatic adenocarcinoma | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) HU (Completed) ES (Ongoing) IT (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2014-004480-20 | Sponsor Protocol Number: GS-US-370-1296 | Start Date*: 2015-05-28 | |||||||||||
Sponsor Name:Gilead Sciences, Inc. | |||||||||||||
Full Title: A Phase 2, Randomized, Double-blind Study of Gemcitabine and Nab-paclitaxel combined with Momelotinib in Subjects with Previously Untreated Metastatic Pancreatic Ductal Adenocarcinoma Preceded by ... | |||||||||||||
Medical condition: Untreated Metastatic Pancreatic Ductal Adenocarcinoma | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: HU (Completed) DE (Completed) ES (Completed) CZ (Ongoing) IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2009-011305-17 | Sponsor Protocol Number: CA046 | Start Date*: 2011-08-18 | |||||||||||
Sponsor Name:Abraxis BioScience, LLC, a wholly-owned subsidiary of Celgene Corporation | |||||||||||||
Full Title: A Randomized Phase III Study of Weekly ABI-007 plus Gemcitabine versus Gemcitabine Alone in Patients with Metastatic Adenocarcinoma of the Pancreas | |||||||||||||
Medical condition: Metastatic Adenocarcinoma of the Pancreas | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Prematurely Ended) ES (Ongoing) BE (Ongoing) AT (Completed) IT (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2010-019588-12 | Sponsor Protocol Number: Bay86-9766/14905 | Start Date*: 2010-08-26 | |||||||||||||||||||||
Sponsor Name:Bayer HealthCare AG | |||||||||||||||||||||||
Full Title: A multi-center, phase I/II study of BAY 86-9766 in combination with gemcitabine in patients with locally advanced inoperable or metastatic pancreatic cancer | |||||||||||||||||||||||
Medical condition: Pancreatic cancer is the eighth most common cause of cancer-related death worldwide, associated with a 5-year survival rate of 5-6%. A vast majority of patients present with incurable advanced dise... | |||||||||||||||||||||||
|
|||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||||||||||||
Trial protocol: DE (Completed) BE (Completed) GB (Ongoing) CZ (Completed) IT (Completed) | |||||||||||||||||||||||
Trial results: View results |
EudraCT Number: 2014-001589-85 | Sponsor Protocol Number: D081FC00001 | Start Date*: 2014-11-03 |
Sponsor Name:Astrazeneca AB | ||
Full Title: A Phase III, Randomised, Double Blind, Placebo Controlled, Multicentre Study of Maintenance Olaparib Monotherapy in Patients with gBRCA Mutated Metastatic Pancreatic Cancer whose Disease Has Not Pr... | ||
Medical condition: Patients with gBRCA mutated metastatic pancreatic cancer whose disease has not progressed on first line platinum based chemotherapy | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: GB (Ongoing) DE (Ongoing) BE (Ongoing) NL (Ongoing) ES (Ongoing) IT (Ongoing) FR (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2010-022757-42 | Sponsor Protocol Number: IMM-101-002 | Start Date*: 2011-05-17 | |||||||||||
Sponsor Name:Immodulon Therapeutics Limited | |||||||||||||
Full Title: A Randomised, Open-Label, Proof-of-Concept, Phase II Trial Comparing Gemcitabine with and without IMM-101 in Advanced Pancreatic Cancer | |||||||||||||
Medical condition: Advanced pancreatic cancer The overall objective of this clinical study is to evaluate a potential synergy between gemcitabine and IMM-101 and any beneficial effect this may have on safety and to... | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Ongoing) ES (Completed) IT (Completed) IE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2009-018240-23 | Sponsor Protocol Number: CO-101-001 | Start Date*: 2010-07-12 | |||||||||||
Sponsor Name:Clovis Oncology Inc | |||||||||||||
Full Title: A phase II Randomized, Open-Label, Multicenter Study Comparing CO-1.01 With Gemcitabine as First-Line Therapy in Patients with Metastatic Pancreatic Adenocarcinoma | |||||||||||||
Medical condition: Metastatic pancreatic cancer | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: BE (Completed) NO (Ongoing) FR (Ongoing) GB (Ongoing) SE (Completed) DE (Completed) IT (Prematurely Ended) NL (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2013-002844-10 | Sponsor Protocol Number: CA209-032 | Start Date*: 2013-11-12 | ||||||||||||||||||||||||||||||||||||
Sponsor Name:Bristol-Myers Squibb International Corporation | ||||||||||||||||||||||||||||||||||||||
Full Title: A Phase 1/2, Open-label Study of Nivolumab Monotherapy or Nivolumab combined with Ipilimumab in Subjects with Advanced or Metastatic Solid Tumors | ||||||||||||||||||||||||||||||||||||||
Medical condition: Advanced or metastatic solid tumors: 1) Triple Negative Breast Cancer (TNBC) 2) Gastric Cancer (GC) 3) Pancreatic Cancer (PC) 4) Small Cell Lung Cancer (SCLC). 5) Bladder Cancer (BC) 6) Ovari... | ||||||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||||||||||||||||||||||
Trial protocol: GB (Ongoing) DE (Ongoing) ES (Ongoing) FI (Ongoing) IT (Ongoing) DK (Ongoing) | ||||||||||||||||||||||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2013-003398-91 | Sponsor Protocol Number: ABI-007-PANC-003 | Start Date*: 2014-05-15 | |||||||||||
Sponsor Name:Celgene Corporation | |||||||||||||
Full Title: A Phase 3, Multicenter, Open-label, Randomized Study of nab-Paclitaxel Plus Gemcitabine versus Gemcitabine Alone as Adjuvant Therapy in Subjects with Surgically Resected Pancreatic Adenocarcinoma | |||||||||||||
Medical condition: Subjects With Surgically Resected Pancreatic Adenocarcinoma | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: CZ (Ongoing) AT (Ongoing) HU (Ongoing) ES (Ongoing) IT (Ongoing) PT (Ongoing) BE (Ongoing) FI (Ongoing) IE (Ongoing) DK (Ongoing) GB (Ongoing) NL (Ongoing) | |||||||||||||
Trial results: (No results available) |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
